DURHAM- Target RWE joins the company’s leadership team by hiring Derek Evans as chairman.
The company announced the news today in a statement.
“In this new role, Derek will lead all operational functions as we continue to leverage our important software, data and intellectual assets and capabilities for our partners,” said Neal Bibeau, CEO of Target RWE.
The company, which acquired Durham-based software analytics company NoviSci, Inc., in January 2021, combined the two startups with financial backing in the form of a strategic investment from Amgen. Amgen announced earlier this year that it would build a facility in Holly Springs and hire up to 355 employees in high-paying positions.
Biotech giant Amgen invests after Durham startups merge in health data deal
The company “designs custom datasets, analyzes and evidence to address the complexity of health evidence questions and quality initiatives,” according to its website. The company can then offer its customers a “turnkey health proof solution that quickly aggregates real-world data,” it says on its website.
The company is also recruiting for other positions, as the careers website lists seven vacancies in Durham.
“Target RWE has taken significant momentum towards realizing the promise of real-world evidence for the healthcare industry, providers and, most importantly, for patients who live with often chronic and comorbid conditions,” said Derek Evans said in a statement.
Life sciences company Amgen chooses Holly Springs for its plant, hundreds of jobs at $120,000
Evans was most recently managing director of business analytics and innovation at Change Healthcare, a provider of a healthcare analytics platform.
“I am delighted to join the organization at this critical time to accelerate the great work that is currently underway,” Evans said in the statement. “Target RWE is on the precipice of healthcare innovation by bringing together unique real-world data, new analytics, and cutting-edge technology at scale to improve healthcare outcomes. With our proprietary technology, we can help our customers make better decisions that speed time to market, reduce capital expenditures and improve patient outcomes. »
Earlier this year, the company announced the addition of Dr. Andrew von Eschenbach as a senior advisor, the company’s statement said.